TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04137055
Drug: ZSP0678-Dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP0678 tablets administered orally once daily for 14 Days
Study: NCT04137055
Drug: ZSP0678 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to ZSP0678 orally.
Study: NCT04019197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo injection
Study: NCT03557229
Drug: Melatonin 5 mg
Normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral: 50 mg once daily for 5 days
Study: NCT03557229
Drug: Vitamin C 1 GM Oral Tablet
Normalized name: vitamin C 1 GM Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral: 1 GM every 6 hours for 5 days
Study: NCT00542425
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous daily
Study: NCT00542425
Drug: BA058 20 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: BA058 20 µg subcutaneous daily
Study: NCT00542425
Drug: BA058 40 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: BA058 40 µg subcutaneous daily
Study: NCT00542425
Drug: BA058 80 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: BA058 80 µg subcutaneous daily
Study: NCT02578095
Drug: VK5211
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT02578095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT02641847
Drug: doxorubicin or epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02641847
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01735019
Drug: Administration of remifentanil with TCI system
Approvals — FDA: no, EMA: no, PMDA: no
Description: A given effect site concentration of remifentanil would be administered to subjects using TCI system. According to biased coin design, the given concentration of remifentanil is determined according to success or failure of just previously enrolled patient. If the former patient did not cough during anesthetic emergence at a given concentration (success), the next patient will be randomly allocated into the same concentration of remifentanil with 18/19 of probability or the lower concentration of remifentanil by 0.4 ng/ml with 1/19 of probability. If the former patient coughed during anesthetic emergence (failure), the next will be automatically allocated into the higher concentration of remifentanil by 0.4 ng/ml.
Study: NCT01115959
Drug: placebo bid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02812394
Drug: Sinemet®
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive carbidopa/levodopa tablets administered every 8 hours.
Study: NCT03809312
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos BID x 10 days
Study: NCT03194204
Drug: Doxycycline Tablets
Normalized name: Doxycycline Tablets
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMP-3 and MMP-9 will be done with blood samples using ELISA technique CIMT will be done using colored doppler ultrasound
Study: NCT02344654
Drug: Urografin
Normalized name: Urografin 150
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01546857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline
Study: NCT00809263
Drug: homeopathic remedy
Normalized name: Quality Choice Homeopathic Remedy Ear Relief Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic remedy 12C potency, 10 drops TID X 7 days
Study: NCT00374127
Drug: Marijuana blunt
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blunts were fabricated by cutting the bottom third off a Dutch Master® cigar, removing all of the cigar tobacco, and replacing it with all of the marijuana contained in a NIDA marijuana cigarette (ca. 800 mg).
Study: NCT00374127
Drug: marijuana cigarette
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana cigarettes were provided by the National Institute on Drug Abuse.
Study: NCT01180465
Drug: LIPO-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIPO-102 High dose
Study: NCT01180465
Drug: LIPO-102, Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03348917
Drug: Plain non antibacterial soap
Normalized name: QSR Antibacterial Soap Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guardian gel hand wash (not medicated),
Study: NCT01388491
Drug: desogestrel/ethinyl estradiol
Normalized name: DESOGESTREL/ETHINYL ESTRADIOL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02079844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast placebo-matching tablets
Study: NCT02079844
Drug: Second generation antipsychotic
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second Generation Antipsychotic (SGA) medication for standard of care therapy will be sourced and managed locally by the site.
Study: NCT00073034
Drug: EAA-090
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00203411
Drug: Capecitabine (Xeloda)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m\^2 administered orally twice daily for two weeks followed by one week rest period
Study: NCT02299206
Drug: Desitin Maximum Strength Original Paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parents/caregivers of subjects will administer Desitin Maximum Strength Original Paste (ingredients: Zinc Oxide 40%) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
Study: NCT03381352
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 825mg/m2 PO BID
Study: NCT01402375
Drug: Hydrocodone (first trial)
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take 1 dose of Hydrocodone 5mg / Acetaminophen 500mg every 4 hours as needed for pain
Study: NCT01402375
Drug: Codeine (first trial)
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
Study: NCT01402375
Drug: Codeine (for second trial)
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
Study: NCT01402375
Drug: Hydrocodone (third trial)
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take 1 dose of Hydrocodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain.
Study: NCT04224987
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin will be administered as a directly observed dose in oral suspension form for children:~1. Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~2. For children 1-11 months of age, weight or age-based dosing will be used~3. For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program
Study: NCT04973722
Drug: LY06006
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/1 ml, once every 6 months administered subcutaneously
Study: NCT02541565
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02541565
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01145404
Drug: Lapatinib plus capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression
Study: NCT01481714
Drug: Sodium picosulphate, magnesium oxid and citric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: * A sachet mixed with 250 mL of water at 18:00 pm~* A sachet mixed with 250 mL of water at 21:00 pm~* A minimum of 4 litres of fluid were recommended throughout the preparation
Study: NCT01481714
Drug: Sodium picosulphate/magnesium oxide and citric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: The day before the procedure:~- A sachet mixed with 250 mL of water at 18:00 pm, followed by 2 litres of clear liquids~The day of the procedure:~* A sachet administered at 5:45 am, followed by 1,5 litres of fluid intake up to 7 am for colonoscopies scheduled from 9 to 11 am.~* A sachet administered at 6:45 am, followed by 1,5 litres of fluid intake up to 8 for colonoscopies scheduled after 11 am.
Study: NCT03128606
Drug: GLPG3067 single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG3067 oral suspension, single ascending doses, daily
Study: NCT03128606
Drug: GLPG3067 oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG3067 oral suspension, single dose, daily
Study: NCT01522898
Drug: Medical Ventricular Rate Control
Normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventricular Rate Control with target ventricular rate of 90 beats per minute.
Study: NCT01911715
Drug: MDV3100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03128606
Drug: GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG3067 matching placebo oral tablet, GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule, multiple doses, daily for 14 days
Study: NCT02496377
Drug: ferrous glycine sulfate Tardyferon
Normalized name: Ferrous glycine sulfate
DrugBank: Ferrous glycine sulfate (DB14501)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02496377
Drug: ferric carboxymaltose Ferinject
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03922711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT04080349
Drug: Dinoprostone 3 mg
Normalized name: dinoprostone 3 MG
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
Study: NCT04080349
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet of placebo inserted by the study nurse 3 hours before IUD insertion
Study: NCT03167034
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Study: NCT02639286
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via SC
Study: NCT00925899
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg melatonin orally every evening about 1 hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of melatonin followed by one week of placebo, or the other way around), the participant may receive melatonin for 6 weeks.
Study: NCT00925899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet orally every evening about one hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of placebo followed by one week of melatonin, or the other way around), the participant may receive melatonin for 6 weeks.
Study: NCT05680389
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg twice daily for 3 months
Study: NCT05680389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily for 3 months
Study: NCT00338442
Drug: VariZIG™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological / Vaccine
Study: NCT03019614
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Generic hydrocortisone
Study: NCT03019614
Drug: Chronocort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified formulation of hydrocortisone
Study: NCT03038321
Drug: sofenacin
Normalized name: solfenacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: solifenacin 10 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation
Study: NCT03038321
Drug: Xefo
Approvals — FDA: no, EMA: no, PMDA: no
Description: lornoxicam 8 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
Study: NCT03011788
Drug: Golytely Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel purge prior to,colonoscopy
Study: NCT00730158
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.
Study: NCT03157401
Drug: intravenous infusion group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
Study: NCT03157401
Drug: intra-articular injection group
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
Study: NCT03157401
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
Study: NCT01958866
Drug: Tinospora Crispa-extract Product
Normalized name: Tinospora cordifolia whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01958866
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00516321
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo taken once daily orally
Study: NCT02447965
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using ultrasound guidance normal saline will be injected into the placebo group's rectus abdominis sheath.
Study: NCT02865681
Drug: HCG trigger
Approvals — FDA: no, EMA: no, PMDA: no
Description: injectable
Study: NCT03880058
Drug: SLI-F06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment
Study: NCT00497991
Drug: AZD1152
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03262935
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: See drug label
Study: NCT03428958
Drug: NUC-3373 + leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUC-3373 + leucovorin
Study: NCT03428958
Drug: NUFOX + VEGF pathway inhibitor
Normalized name: Hedgehog pathway inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUC-3373 + oxaliplatin + bevacizumab
Study: NCT03428958
Drug: NUFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUC-3373 + irinotecan
Study: NCT03428958
Drug: NUFIRI + VEGF pathway inhibitor
Normalized name: Hedgehog pathway inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUC-3373 + irinotecan + bevacizumab
Study: NCT01507038
Drug: YH14617
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6mg once weekly
Study: NCT01507038
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly
Study: NCT03880058
Drug: Formulation buffer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment
Study: NCT00549640
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-active (sugar pill)designed to be a look-alike to the methylphenidate. Given at the same frequency and dosage look-alike to the active comparator (methylphenidate 54 mg)
Study: NCT01599104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to LCZ696 or Olmesartan
Study: NCT00091650
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01477073
Drug: FSH-GEX™
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01477073
Drug: recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01477073
Drug: urinary FSH
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01477073
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03628391
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for ICU delirium, titrated on validated screening tool-based diagnosis
Study: NCT00636155
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg/m2 on days 2, 3, and 4
Study: NCT01715168
Drug: DOXIL/CAELYX
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004654
Drug: soy protein isolate
Normalized name: Soy Protein Isolate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02705755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT02382328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral pills, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
Study: NCT00141349
Drug: UK-369,003
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00226772
Drug: OMS103HP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours
Study: NCT00226772
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
Study: NCT01303445
Drug: Aggrenox alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggrenox 1 capsule twice daily for 7 days
Study: NCT02014129
Drug: LY2835219
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02186769
Drug: Risperdal® Consta®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02186769
Drug: LY03004
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04667780
Drug: Standard COVID-19 care
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per the hospital guidelines
Study: NCT02182323
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00779181
Drug: ADX415
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADX415 taken three times a day to achieve a low total daily dose
Study: NCT00779181
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken three times a day
Study: NCT02371980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine placebo-matching capsules
Study: NCT01992900
Drug: eurartesim film coated tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first dose of Eurartesim film coated tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. tablet will be crushed and dispersed in a few amount of water (about 10 ml).
Study: NCT03780686
Drug: Norepinephrine, dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: drugs to decrease bleeding
Study: NCT04315298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple intravenous (IV) doses of placebo to match sarilumab administration
Study: NCT00542789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily oral
Study: NCT03647969
Drug: mFOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin at a dose of 400 mg/m2 iv over two hours (day 1), Fluorouracil at a dose of 400 mg/m² iv bolus (day 1), and Fluorouracil at a dose of 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks
Study: NCT00654394
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00131638
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.
Study: NCT00175292
Drug: Probiotic - VSL#3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02568735
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After total hip replacement surgery patient were given either etoricoxib or dexketoprofen
Study: NCT04393675
Drug: LT5001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered twice daily
Study: NCT04393675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered twice daily
Study: NCT00025597
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00025597
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00142558
Drug: MK0663; etoricoxib / Duration of Treatment: 5 Days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01456286
Drug: sapropterin
Normalized name: Sapropterin
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: two weeks of treatment: 5 mg/kg per day during first week 10 mg/kg per day during second week
Study: NCT00142558
Drug: Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02089178
Drug: sevoflurane-remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01134237
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline as a placebo for control arm
Study: NCT00599716
Drug: vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical to proprietary formulation of active eye drop but without active ingredient, sodium hyaluronate
Study: NCT02847702
Drug: VM902A 200-mg Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally with food twice daily
Study: NCT00325949
Drug: Extended release hydrocodone and acetaminophen (Vicodin CR)
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets BID
Study: NCT00325949
Drug: hydrocodone/acetaminophen extended release (Vicodin CR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet BID